U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT06967233) titled 'Multimodal Managements for Metastatic Pancreatic Cancer.' on May 02.
Brief Summary: Pancreatic ductal adenocarcinoma (PDAC) remains a challenging malignancy, with over 300,000 patients diagnosed annually worldwide. Patients with metastatic pancreatic cancer (MPC) are generally not considered appropriate for operative management because it would not improve their prognosis.
Developments in modern surgery and systemic treatment over the past decade have substantially improved the oncological outcomes for patients with PDAC. The prognosis can be further improved by using novel combined regimens. Systemic treatment is advantageous as it...